Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine

Published: Monday, June 27, 2011
Last Updated: Monday, June 27, 2011
Bookmark and Share
Alvetex® enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.

Reinnervate, has announced that alvetex®, its breakthrough 3D cell culture technology, is among the winners of the prestigious 49th Annual R&D 100 Awards.

Alvetex® is a unique and proprietary cell culture scaffold that, for the first time, enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.

Reinnervate launched its first product, the alvetex® 12-well plate, in Europe at the end of November 2010 and introduced 6-well and 12-well inserts and petri dish formats at the end of March 2011.

The Company intends to launch alvetex® products in a range of other formats over the next 12 months, including 24, 48 and 96 well plates.

Alvetex was chosen by an independent judging panel and the editors of R&D Magazine to be among the 100 most technologically significant products introduced into the marketplace over the past year.

The award will be presented to reinnervate at a special Gala Awards Banquet at the Renaissance Orlando Hotel at SeaWorld in Florida on 13th October 2011.

“The editors were impressed with the strong field of candidates for this year’s R&D 100 Awards. The number and quality of entrants far exceeded that of recent years,” said Rita Peters, editorial director of R&D Magazine.

Professor Stefan Przyborski, reinnervate’s Chief Scientific Officer and founder, commented: “We are extremely proud that alvetex® has been selected as one of this year’s winners of the annual R&D 100 Awards. The team here at reinnervate and at Durham University have shown great dedication in bringing our game-changing alvetex® technology to market and this award goes some way towards recognizing their work. Here at reinnervate we continue to innovate and intend to launch further alvetex® products onto the market over the next 12 months, including a 96-well plate suitable for high-throughput drug screening.”

Since 1963, the R&D 100 Awards have identified revolutionary technologies newly introduced to the market, many of which have become household names.

Winners are picked from industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology and represent a cross-section of industry, academia, private research firms and government labs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reinnervate Partners with Oncotest and SBH Sciences
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.
Thursday, October 31, 2013
Reinnervate Ltd and Roslin Cellab Partner
Reinnervate Ltd announced that it is entering into a collaboration with Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.
Friday, September 20, 2013
3D cell Culture Firm Reinnervate and Specialist Oncology CRO Oncotest GmbH Enter Collaboration Agreement
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology.
Monday, January 07, 2013
Reinnervate and Tecan Sign Co-marketing Agreement
Both Companies to develop automated 3D cell culture solutions for improved cellular assays.
Tuesday, November 27, 2012
Reinnervate and Roslin Cellab Announce Plans to Collaborate
Collaboration on the development of protocols for three dimensional growth of hESC’s using Alvetex®Scaffold.
Friday, April 27, 2012
Reinnervate and Kirkstall to Collaborate on New 3D Cell Culture Products
Companies will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012. The two UK companies develop cell culture systems that bridge the current gap between 2D in-vitro cell culture and animal models.
Monday, March 19, 2012
New Reinnervate Whitepaper Includes Details on Live 3D Cell Imaging in 3D Cell Culture Using Alvetex®
The release is set to help scientists make the switch from traditional 2D cell culture to 3D cell growth.
Monday, January 30, 2012
Reinnervate and Mirus Bio announce collaboration
Reinnervate and Mirus Bio announce commercial agreement to launch new range of products for the transfection of cells cultured in 3D.
Friday, November 18, 2011
Reinnervate Partners with AMS Biotechnology (Europe) Limited for Distribution of Alvetex®
Alvetex® is a unique and proprietary cell culture scaffold that enables genuine 3D cell growth to be performed routinely and cost-effectively in cell biology laboratories.
Wednesday, June 01, 2011
Reinnervate Enhances Commercial and Product Development Teams with Key Senior Appointments
Appointments of Richard Rowling as commercial director and Barry Lynch as marketing manager to lead the sales and marketing operations supporting alvetex®.
Wednesday, April 06, 2011
Alvetex® Named in the “Top Ten Life Science Innovations of 2010” by The Scientist Magazine
Reinnervate’s 3D cell culture technology selected as one the ten most exciting new tools to hit the life sciences market this year.
Monday, December 06, 2010
Reinnervate Partners with LGC for Global Distribution of Alvetex®
Additional collaboration to develop 3d cell cultures for applications in drug discovery and development.
Tuesday, November 30, 2010
Reinnervate Partners with LGC for Global Distribution of ALVETEX®
Additional collaboration to develop 3D cell cultures for applications in drug discovery and development.
Monday, November 29, 2010
Reinnervate Completes Expansion into New Purpose-Built Facility at Netpark
Reinnervate, a life sciences company driving the adoption of routine 3D cell culture, has announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.
Tuesday, November 16, 2010
Reinnervate Launches new Website with Interactive Technical Resource for Routine 3D Cell Culture
New site provides scientific and technical information on 3D cell culture based on Reinnervate’s core Alvetex® technology.
Wednesday, October 13, 2010
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos